

DAFTAR PUSTAKA

1. Soelistijo SA, Lindarto D, Decroli E, Permana H, Sucipto KW, Kusnandi Y, Budiman, Iksan MR, Sasiarini L, Sanusi H. Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 dewasa di Indonesia 2019. Jakarta: PB Perkeni;2019.
2. Kemkes. Tahun 2030 prevalensi diabetes melitus di Indonesia mencapai 21,3 juta orang. 2009.
3. Syamsari SM. Diabetes Melitus [Internet]. 2021 [cited 2021 Sep 23]. Available from: <https://portal.takalarkab.go.id/diabetes-melitus/>
4. Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c test in diagnosis and prognosis of diabetic patients. Biomark Insights. 2016;11:95-104.
5. Song J, Xian D, Yang L, Xiong X, Lai R, Zhong J. Pruritus: Progress toward pathogenesis and treatment. BioMed Res Int. 2018; 1–12.
6. Stefaniak A, Chlebicka I, Szepietowski J. Itch in diabetes: A Common underestimated problem. Adv Dermatol Allergol. 2019;38(2):1-8.
7. Phoebus A. Hubungan Kadar Hba1c terhadap Derajat Keparahan Pruritus pada Penderita Diabetes Melitus Tipe 2 di Rumah Sakit Umum Pusat Haji Adam Malik. 2016 [cited 2021 Sept 1]; Available from: <https://repository.usu.ac.id/bitstream/handle/123456789/20312/130100242.pdf?sequence=1&isAllowed=y>.
8. Bustan RS, Wasim D, Yderstræde KB, Bygum A. Specific skin signs as a cutaneous marker of diabetes mellitus and the prediabetic state – a systematic review. Danish Medical Journal. 2017;64(1):1-9.
9. Yusharyahya SN, Legiawati L, Bianti M. Kualitas hidup pasien usia lanjut dengan pruritus kronik dinilai dengan Dermatology Life Quality Index (DLQI). MDVI. 2017;44(2):55–59.
10. Diabetsatlas. ID Diabet atlas seventh edition. Karakas Print; 2015.
11. Tjandrawinata RR. Patogenesis diabetes tipe 2: Resistensi insulin dan defisiensi insulin. Dexa Laboratories of Biomolecular Sciences (DLBS).

- 2016; 1-5.
12. Ohiagu FO, Chikezie PC, Chikezie CW. Pathophysiology of diabetes mellitus complications: Metabolic events and control. *Biomed Res Ther.* 2021;8(3):4243–4257.
 13. Nawale RB, Mourya VK, Bhise SB. Non-enzymatic glycation of proteins: A Cause for complications in diabetes. *Indian J Biochem Biophys.* 2006;43:337-344.
 14. Soebroto C. Manifestasi dermatologis pada pasien diabetes melitus. *Damaianus Journal of Medicine.* 2011;10(3):171-176.
 15. Giacco F, Brownlee M, Schmidt AM. Oxidative stress and diabetic complications. Schmidt AM, editor. *Circ Res.* 2010;107(9):1058–1070.
 16. Sharma C, Kaur A, Thind SS, Singh B, Raina S. Advanced glycation End-products (AGEs): an Emerging concern for processed food industries. *J Food Sci Technol.* 2015;52(12):7561–7576.
 17. Perrone A, Giovino A, Benny J, Martinelli F. Advanced Glycation End Products (AGEs): biochemistry, signaling, analytical Methods, and epigenetic effects. *Oxid Med Cell Longev.* 2020;1–186.
 18. Buse MG. Hexosamines, insulin resistance, and the complications of diabetes: Current status. *Am J Physiol-Endocrinol Metab.* 2006;290(1):E1–E8.
 19. Figueroa-Romero C, Sadidi M, Feldman EL. Mechanisms of disease: The Oxidative stress theory of diabetic neuropathy. *Rev Endocr Metab Disord.* 2008;9(4):301–314.
 20. Yan L. Redox imbalance stress in diabetes mellitus: Role of the polyol pathway. *Anim Models Exp Med.* 2018;1(1):7–13.
 21. Newton AC. Protein kinase C: perfectly balanced. *Crit Rev Biochem Mol Biol.* 2018;53(2):208–230.
 22. Neilly J, Martin A, Simpson N. Pruritus in Diabetes Mellitus: Investigation of Prevalence and Correlation With Diabetes Control. *Diabetes Care.* 1986;9(3):273-275.
 23. Ko MJ, Chiu HC, Jee SH, Hu FC, Tseng CH. Postprandial blood glucose is

- associated with generalized pruritus in patients with type 2 diabetes. Eur J Dermatol. 2013;23(5):688–693.
24. Yamaoka H, Sasaki H, Yamasaki H, Ogawa K, Ohta T, Furuta H, dkk. Truncal Pruritus of Unknown Origin May Be a Symptom of Diabetic Polyneuropathy. Diabetes Care. 2010;33(1):150–155.
 25. Valdes R, Mollanazar N, González-Muro J, Nattkemper L, Torres-Alvarez B, López F, dkk. Itch Prevalence and Characteristics in a Hispanic Geriatric Population: A Comprehensive Study Using a Standardized Itch Questionnaire. Acta Derm Venereol. 2015;95(4):417–421.
 26. Spravchikov N, Sizyakov G, Gartsbein M, Accili D, Tennenbaum T, Wertheimer E. Glucose effects on skin keratinocytes: Implications for diabetes skin complications. Diabetes. 2001;50(7):1627–1635.
 27. Seité S, Khemis A, Rougier A, Ortonne J. Importance of treatment of skin xerosis in diabetes. J Eur Acad Dermatol Venereol. 2011;25(5):607–609.
 28. Tabatabaei Malazy O, Shariat M, Heshmat R, Majlesi F, Alimohammadian M, Khaleghnejad Tabari N, dkk. Vulvovaginal candidiasis and its related factors in diabetic women. Taiwan J Obstet Gynecol. 2007;46(4):399–404.
 29. Sun Pi-Chang, Chen Chen-Seng, Kuo Cheng-Deng, Lin Hong-Da, Chan Rai-Chi, Kao Mu-Jung, Wei Shun-Hwa. Impaired microvascular flow motion in subclinical diabetic feet with sudomotor dysfunction. Microvasc Res. 2012;83(2):243–248.
 30. Al-Mutairi N, Zaki A, Sharma AK, Al-Sheltawi M. Cutaneous manifestations of diabetes mellitus. Med Princ Pract. 2006;15(6):427–430.
 31. Rosati D, Bruno M, Jaeger M, ten Oever J, Netea MG. Recurrent vulvovaginal candidiasis: An Immunological Perspective. Microorganisms. 2020;8(2):144.
 32. Nobile CJ, Johnson AD. *Candida albicans* biofilms and human disease. Annu Rev Microbiol. 2015;69(1):71–92.
 33. Rodrigues CF, Rodrigues ME, Henriques M. Candida sp. Infections in patients with diabetes mellitus. J Clin Med. 2019;8(1):76.
 34. Duff M, Demidova O, Blackburn S, Shubrook J. Cutaneous manifestations of

- diabetes mellitus. *Clin Diabetes*. 2015;33(1):40–48.
35. Aguilar-Luelmo J, Santandreu MS. Folliculitis: Recognition and management. *Am J Clin Dermatol*. 2004;5(5):301–310.
 36. Nakatani K, Kurose T, Hyo T, Watanabe K, Yabe D, Kawamoto T, dkk. Drug-Induced Generalized Skin Eruption in a Diabetes Mellitus Patient Receiving a Dipeptidyl Peptidase-4 Inhibitor Plus Metformin. *Diabetes Ther*. 2012;3(1):14.
 37. Herman G, Stevens C, Vandyck K, Bergman A, Yi B, Desmet M, dkk. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses. *Clin Pharmacol Ther*. 2005;78(6):675–688.
 38. Scott LJ. Sitagliptin: A Review in Type 2 Diabetes. *Drugs*. 2017;77(2):209–224.
 39. Riad H, Al Ansari H, Mansour K, Al Mannai H, Al Sada H, Abu Shaikha S, dkk. Pruritic vesicular eruption on the lower legs in a diabetic female. Case Rep Dermatol Med. 2013:1–4.
 40. Tanaka K, Ogawa Y, Shimada S. Drug eruption caused by sitagliptin, a dipeptidyl peptidase-IV inhibitor. *J Dermatol*. 2012;39(8):726–728.
 41. Hong S, Park J, Ihm C, Kim N. Acquired perforating dermatosis in patients with chronic renal failure and diabetes mellitus. *J Korean Med Sci*. 2004;19(2):283-288.
 42. Yuzuk S, Trau H, Stempler D, Sofer E, Levy A, Schewach-Millet M. Reactive perforating collagenosis. *Int J Dermatol*. 1985;24(9):584–586.
 43. Bonamigo RR, Dornelles SIT. Dermatology in public health environments. Brazil: Springer;2018.
 44. Weisshaar E, Szepietowski J, Darsow U, Misery L, Wallengren J, Mettang T, dkk. European Guideline on Chronic Pruritus. *Acta Derm Venereol*. 2012;92(5):563–581.
 45. Proksch E. The role of emollients in the management of diseases with chronic dry skin. *Skin Pharmacol Physiol*. 2008;21(2):75–80.

46. A. E. Elhaj N, S. Ali H, Abu-Aгла H, O. Alfarouk K, A. Elbadawi R, N. Aljarbou A, dkk. The prevalence of pruritis among sudanese patients with diabetes mellitus. *Am J Dermatol Venereol.* 2019;9(5):73–83.
47. Pandey S, Mishra P, Sharma N, B.K. S. Dermatological manifestations in diabetes mellitus at NGMCTH Kohalpur. *J Nepalgunj Med Coll.* 2017;13(2):31–34.
48. Twycross R. Itch: Scratching more than the surface. *QJM.* 2003;96(1):7–26.
49. Moses, S. Pruritus. *American Family Physician.* 2003;68(6):1135-1142.
50. Ständer S, Weisshaar E, Mettang T, Szepietowski J, Carstens E, Ikoma A, dkk. Clinical Classification of Itch: a Position Paper of the International Forum for the Study of Itch. *Acta Derm Venereol.* 2007;87(4):291–294.
51. Venos E, de Koning L. Endocrine markers of diabetes and cardiovascular disease risk. Chapter 6. *Endocrine Biomarkers.* Elsevier. 2017:251-289.
52. Campbell L, Pepper T, Shipman K. HbA1c: A Review of non-glycaemic variables. *J Clin Pathol.* 2018;0:1-8.
53. Imran SA, Rabasa-Lhoret R, Ross S. Targets for glycemic control. *Can J Diabetes.* 2013;37:S31–S34.
54. Gallagher EJ, Le Roith D, Bloomgarden Z. Review of hemoglobin A1c in the management of diabetes. *J Diabetes.* 2009;1(1):9–17.
55. Phan N, Blome C, Fritz F, Gerss J, Reich A, Ebata T, dkk. Assessment of pruritus Intensity: Prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. *Acta Derm Venereol.* 2012;92(5):502–507.
56. Reich A, Heisig M, Phan N, Taneda K, Takamori K, Takeuchi S, dkk. Visual analogue scale: Evaluation of the instrument for the assessment of pruritus. *Acta Derm Venereol.* 2012;92(5):497–501.
57. Kayiran MA, Akdeniz N. Diagnosis and treatment of urticaria in primary care. *North Clin Istanb.* 2019;6(1): 93-99.
58. Levey AS, Eckardt Kai-Uwe, Tsukamoto Y, Levin A, Coresh J, Rossert J, dkk. Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO).

- Kidney Int. 2005;67(6):2089–2100.
59. Doubleday AR, Sippel RS. Hyperthyroidism. Gland Surg. 2019;9(1):124–125.
 60. Düll MM, Kremer AE. Management of chronic hepatic itch. Dermatol Clin. 2018;36(3):293–300.
 61. Hunaifi I, Agustriadi IGNO, Asmara IGY, Budyono C. The correlation between HbA1c and neuropathy disability score in type 2 diabetes. Acta Med Indones - Indones J Intern Med. 2021;53(2):164-168.
 62. Stefaniak AA, Krajewski PK, Bednarska-Chabowska D, Bolanowski M, Mazur G, Szepietowski JC. Itch in Adult Population with Type 2 Diabetes Mellitus: Clinical Profile, Pathogenesis and Disease-Related Burden in a Cross-Sectional Study. Biology. 2021;10(12):1332.
 63. Moses S. Pruritus. Am Fam Physician. 2003;68(6):1135–42.